Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review

Health Technology Assessment

Volumn 5, Issue 1, 2001, Pages

  Clegg, A ^a   Bryant, J ^a   Nicholson, T ^a   McIntyre, L ^a   De Broe, S ^a   Gerard, K ^a   Waugh, N ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG MEGADOSE; ECONOMIC EVALUATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LIVER TOXICITY; META ANALYSIS; MOOD; NOSE DISEASE; OUTCOMES RESEARCH; PAIN; PREVALENCE; QUALITY OF LIFE; REVIEW; URINARY TRACT INFECTION; VERTIGO;

ALZHEIMER DISEASE; CARBAMATES; COST-BENEFIT ANALYSIS; GALANTAMINE; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES;

EID: 18544403400     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
2. Diagnostic testing and dementia
3. Predictors of survival with Alzheimer's disease: A community based study
4. Survival of outpatients with Alzheimer-type dementia
5. Risk of death from Alzheimer's disease in a community population of older persons
6. Accuracy of clinical diagnosis of Alzheimer's disease
7. The investigation of dementia: Results in 200 consecutive admissions
8. The use of CAT scanning in dementia: A systematic review
9. A survey of memory clinics in the British Isles
10. Memory clinics: Past, present and future
11. Southampton Memory Clinic: Important information for general practitioners
12. North of England evidence-based guidelines development project: Guidelines for the primary care management of dementia
13. Personal paper. New drug treatment for Alzheimer's disease: Lessons for healthcare policy
14. Advertisements for donepezil
15. Advertisements for donepezil
16. Advertisements for donepezil
17. Dementia
18. Donepezil update
19. Donepezil. Moderate efficacy in Alzheimer's disease
20. Therapy of the cognitive deficit in Alzheimer's disease: The cholinergic system
21. Guidelines for authors and peer reviewers of economic submissions to the BMJ
22. Assessing the quality of reports of randomised clinical trials: Is blinding necessary?
23. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review)
24. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis
25. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
26. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
27. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study
28. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
29. Donepezil therapy in clinical practice: A randomized crossover study
30. Rivastigmine for Alzheimer's disease
31. Safety / tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
32. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer's type
33. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
34. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon registered)
35. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
36. Galanthamine hydrobromide: Interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type
37. A 5-month, randomised, placebo-controlled trial of galantamine in AD
38. Galantamine in AD. A 6-month randomised, placebo-controlled trial with a 6-month extension
39. Toward a peer review process for medical decision analysis models
40. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil
41. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model
42. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
43. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
44. Estimating long term cost savings from treatment of Alzheimer's disease: A modelling approach
45. Potential savings in the cost of caring for Alzheimer's disease - Treatment with rivastigmine
46. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine
47. Cognitive function and the costs of Alzheimer disease: An exploratory study
48. Problems using modelling in the economic evaluation of health care
49. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group
50. Is the intervention cost-effective
51. Rapid and responsive health technology assessment: The development and evaluation process in the South and West region of England
52. Elderly people with advanced cognitive impairment in England: Resource use and costs
53. The hazards of scoring the quality of clinical trials for meta-analysis
54. Donepezil enhances global function, cognition, and activities of daily living compared with placebo in a one year, double-blind trial in patients with mild to moderate Alzheimer's disease
55. Rivastigmine. A review of its use in Alzheimer's disease
56. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: Results of a 30-week phase III trial
57. Clinical benefits are maintained during long-term treatment of Alzheimers disease with acetylcholinestrase inhibitor, E2020
58. Canadian study of health and aging: Study methods and prevalence of dementia
59. The economic burden of Alzheimer's disease care
60. Costs of mini mental state examination-related cognitive impairment
61. Relation between severity of Alzheimer's disease and costs of caring
62. Alzheimer's disease: The burden of the illness in England
63. Predicting time to nursing home care and death in individuals with Alzheimer disease
64. Health utilities in Alzheimer's disease: A cross-sectional study of patients and caregivers